Filtered By:
Drug: Metformin

This page shows you your search results in order of relevance. This is page number 7.

Order by Relevance | Date

Total 9821 results found since Jan 2013.

The pharmacogenetics of type 2 diabetes: a systematic review.
CONCLUSIONS We found evidence of pharmacogenetic interactions for metformin, sulfonylureas, repaglinide, thiazolidinediones, and acarbose consistent with their pharmacokinetics and pharmacodynamics. While high-quality controlled studies with prespecified analyses are still lacking, our results bring the promise of personalized medicine in diabetes one step closer to fruition. PMID: 24558078 [PubMed - in process]
Source: Diabetes Care - February 22, 2014 Category: Endocrinology Authors: Maruthur NM, Gribble MO, Bennett WL, Bolen S, Wilson LM, Balakrishnan P, Sahu A, Bass E, Kao WH, Clark JM Tags: Diabetes Care Source Type: research

Study to determine the durability of glycaemic control with early treatment with a vildagliptin–metformin combination regimen vs. standard‐of‐care metformin monotherapy—the VERIFY trial: a randomized double‐blind trial
This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - May 23, 2014 Category: Endocrinology Authors: S. Del Prato, J. E. Foley, W. Kothny, P. Kozlovski, M. Stumvoll, P. M. Paldánius, D. R. Matthews Tags: Research Article Source Type: research

Current use of metformin in addition to insulin in pediatric patients with type 1 diabetes mellitus: an analysis based on a large diabetes registry in Germany and Austria
ConclusionAdditional metformin therapy in T1DM is primarily used in obese females. Additional therapy with metformin was associated with minor benefits.
Source: Pediatric Diabetes - August 18, 2014 Category: Endocrinology Authors: Katja Konrad, Nicolin Datz, Ilse Engelsberger, Jürgen Grulich‐Henn, Thomas Hoertenhuber, Burkhild Knauth, Thomas Meissner, Susanna Wiegand, Joachim Woelfle, Reinhard W. Holl, Tags: Original Article Source Type: research

Prediabetes Diagnosis and Treatment in Primary Care
Conclusions: Our findings show that there are missed opportunities for diabetes prevention in primary care. Providers need to change their approach to prediabetes and play a more effective role in preventing diabetes.
Source: Journal of the American Board of Family Medicine - March 8, 2016 Category: Primary Care Authors: Mainous, A. G., Tanner, R. J., Baker, R. Tags: Brief Reports Source Type: research

Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers.
Authors: Anderson J, Thieu V, Boye KS, Hietpas RT, Garcia-Perez LE Abstract Approximately 90% of T2D patients in the US are diagnosed and treated in the primary care setting, and the majority of the burden of disease management falls to primary care providers. Here, we discuss the clinical data for once weekly dulaglutide, e.g. the results of seven completed Phase 3 trials, patient preference studies, patient reported outcomes (PRO), and clinical data surrounding the dulaglutide administration device. Dulaglutide 1.5 mg once weekly demonstrated superiority to placebo, metformin, sitagliptin, exenatide BID, and insu...
Source: Postgraduate Medicine - August 6, 2016 Category: Internal Medicine Tags: Postgrad Med Source Type: research

Impact of Active Antihyperglycemic Components as herbal therapy for Preventive Health Care Management of Diabetes.
Abstract Diabetes is a metabolic hyperglycemic condition that progressively develops, effect small and large sensory fibers in affected population. It has various complications as hypertension, coronary artery disease, stroke, blindness, kidney disease as well as peripheral neuropathy. Sulfonylureas, thiazolidinediones, metformin, biguanidine, acarbose and insulin are commonly used drugs by diabetic patients, but these all have certain side effects. Even metformin, that is known as the miracle drug for diabetes has been found to be associated with side effects, as during treatment it involves complications with ey...
Source: Current Molecular Medicine - February 19, 2019 Category: Molecular Biology Authors: Kashyap H, Gupta S, Bist R Tags: Curr Mol Med Source Type: research

Psychotropic Medications Are Associated With Increased Liver Disease Severity in Pediatric Nonalcoholic Fatty Liver Disease
Objectives: The aim of the study was to determine whether pediatric patients with nonalcoholic fatty liver disease (NAFLD) exposed to psychotropic medications have more severe liver disease compared to their counterparts who are not on these medications. We hypothesize that use of psychotropic agents is associated with liver disease severity. Methods: Children and adolescents with biopsy-confirmed NAFLD were included in this study. Histology data, detailed clinical information, and results of serum biochemistries performed within 3 months of the liver biopsy were collected retrospectively. Univariate and multivariate ...
Source: Journal of Pediatric Gastroenterology and Nutrition - August 23, 2019 Category: Gastroenterology Tags: Original Articles: Hepatology Source Type: research

Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?
This article provides guidance on integrating oral semaglutide into clinical practice in primary care. Patient populations with T2D who may gain benefit from oral semaglutide include those with inadequate glycemic control taking one or more oral glucose-lowering medication (e.g. after metformin), patients for whom weight loss would be beneficial, patients at risk of hypoglycemia, those who would historically have been considered for treatment with a subcutaneous GLP-1RA, and those receiving basal insulin who require treatment intensification. Like other GLP-1RAs, oral semaglutide is contraindicated in those with personal/f...
Source: Postgraduate Medicine - August 21, 2020 Category: Internal Medicine Tags: Postgrad Med Source Type: research

Determinants of vitamin B12 deficiency in patients with type-2 diabetes mellitus  - A primary-care retrospective cohort study
CONCLUSIONS: Primary-care screening for B12 deficiency should be part of the annual laboratory review of patients with T2DM regardless of the duration of T2DM -especially when they are prescribed ≥ 1.5 g/day of metformin; ≥ 80 years old; vegetarian; and not prescribed B12 supplementation. Concurrent evaluation for associated folate (vitamin B9) deficiency is essential when addressing T2DM-associated B12 deficiencies. Current "Metformin daily dose" is an accurate proxy of both cumulative metformin exposure and duration of T2DM.PMID:37081390 | PMC:PMC10116480 | DOI:10.1186/s12875-023-02057-x
Source: Primary Care - April 20, 2023 Category: Primary Care Authors: Andrew Kien Han Wee Rehena Sultana Source Type: research

Do patients with prediabetes managed with metformin achieve better glycaemic control? A national study using primary care medical records
CONCLUSION: The higher HbA1c and FBG baseline levels among patients with 'incident' prediabetes managed with metformin improved after 6-12 months of starting pharmacological management, and the effect persisted for up to 24 months. Management with metformin could prevent further deterioration of glycaemic levels.PMID:37381113 | DOI:10.1111/dme.15170
Source: Molecular Medicine - June 29, 2023 Category: Molecular Biology Authors: Mingyue Zheng None Soumya Mumtaz Begum Carla De Oliveira Bernardo Nigel Stocks Habiba Jahan David Gonzalez-Chica Source Type: research

Baylor College of Medicine receives sizable grant from Komen for cancer research
Researchers from Baylor College of Medicine in Houston received $960,000 from Susan G. Komen for the Cure to advance breast cancer research. Dr. Sao Jiralerspong, assistant professor in the Lester and Sue Breast Center at BCM, was awarded a $450,000 grant to explore the lab potential of metformin, a diabetes drug, to reduce the threat that ductal carcinoma in situ will spread and develop into a more invasive type of cancer. Dr. Melissa Bondy, professor of pediatrics in hematology and oncology,…
Source: bizjournals.com Health Care:Hospitals headlines - August 1, 2013 Category: Hospital Management Authors: Bayan Raji Source Type: research

A Year in Review: FDA 2015 New Drug Approvals
The approval of first-of-a-kind drugs rose last year to forty-one, resulting in the highest level of newly approved U.S. drugs in nineteen years. The total number of new drugs approved last year was even higher at sixty-nine. The rising figures reflect an industry-wide desire to research and develop drugs for rare and hard-to-treat diseases. The newly approved drugs serve to advance medical care and the health of patients suffering from many ailments, including various forms of cancer, heart failure, and cystic fibrosis. Additionally, more than 40% of the new therapies were approved for treatment of rare or "orphan" dise...
Source: Policy and Medicine - January 13, 2016 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs

Prescribing of metformin based on estimated GFR rather than serum creatinine expands the eligible population and is likely safe
Commentary on: Tuot DS, Lin F, Shlipak MG, et al.. Potential impact of prescribing metformin according to eGFR rather than serum creatinine. Diabetes Care 2015;38:2059–67. Context Metformin is the only oral antidiabetic drug shown to improve cardiovascular outcomes. A common clinical conundrum facing practitioners while using metformin is the potential risk of lactic acidosis (LA) which has a high mortality rate. Hence, according to the product information, metformin has several contraindications including renal impairment. However, recent studies have questioned some of these contraindications. In particular it has ...
Source: Evidence-Based Medicine - March 21, 2016 Category: Internal Medicine Authors: Castelino, R. L., Peterson, G. Tags: Epidemiologic studies, Diet, Renal medicine, Diabetes Therapeutics/Prevention Source Type: research

PodMed – Week of January 9, 2017
This week’s topics include managing earwax, metformin and other diseases, atypical antipsychotics in palliative care, and firearm purchase without a background check. Program notes: 0:51 Managing ear wax 1:51 Industry relative to removal 2:53 Putting cotton swabs not good 3:31 Metformin use and comorbidities 4:31 Does metformin increase or decrease mortality? 5:34 Firearm purchase without […]
Source: Johns Hopkins Medicine Weekly Health News - January 6, 2017 Category: Consumer Health News Authors: Elizabeth Tracey Johns Hopkins Medicine Tags: All Podcasts Chronic Disease Death and Dying Diabetes Geriatrics Mental health PodMed Source Type: podcasts